<div id="readability-page-1" class="page"><div>SAN DIEGO, Aug. 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of Hims &amp; Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the “Class Period”), have until this upcoming Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims &amp; Hers class action lawsuit. Captioned Sookdeo v. Hims &amp; Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims &amp; Hers class action lawsuit charges Hims &amp; Hers as well as certain of Hims &amp; Hers’ executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims &amp; Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Hims &amp; Hers class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-hims-hers-health-inc-class-action-lawsuit-hims.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. CASE ALLEGATIONS: Hims &amp; Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims &amp; Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims &amp; Hers platform.” The Hims &amp; Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims &amp; Hers was engaged in the “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk”; and (ii) as a result, there was a substantial risk that Hims &amp; Hers’ collaboration with Novo Nordisk would be terminated. The Hims &amp; Hers class action lawsuit further alleges that on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims &amp; Hers “based on Hims &amp; Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.” On this news, the price of Hims &amp; Hers stock fell more than 34%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims &amp; Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims &amp; Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims &amp; Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims &amp; Hers class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims &amp; Hers class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman &amp; Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman &amp; Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@rgrdlaw.com <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE5qZzBNQ00zTVRFeE9EVXlJekl4TXpZMU56az0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE5qZzBNQ00zTVRFeE9EVXlJekl4TXpZMU56az0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2Y1NDdiNWUtYzRhZS00OTViLTk5NzAtM2E1NjI0MzlkZGRmLTExNDgxNTAtMjAyNS0wOC0yMy1lbg==/tiny/Robbins-Geller-Rudman-Dowd-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2Y1NDdiNWUtYzRhZS00OTViLTk5NzAtM2E1NjI0MzlkZGRmLTExNDgxNTAtMjAyNS0wOC0yMy1lbg==/tiny/Robbins-Geller-Rudman-Dowd-LLP.png"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/a2879a30-a9fa-457e-97f6-7e2cd2528b7b/small/rgrd-logo-2-jpg.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="150" height="74" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/a2879a30-a9fa-457e-97f6-7e2cd2528b7b/small/rgrd-logo-2-jpg.jpg"/></div></div>

HIMS

Robbins Geller Rudman & Dowd LLP 宣佈了 Hims & Hers Health, Inc. (NYSE: HIMS) 投資者申請成為集體訴訟主原告的截止日期。該訴訟指控違反證券交易法，源於對 Hims & Hers 在銷售 Wegovy® 方面採取欺騙性行為的指控，並且在諾和諾德終止合作後，股價大幅下跌。遭受 2025 年 4 月 29 日至 2025 年 6 月 23 日期間損失的投資者可以在 2025 年 8 月 25 日之前申請

INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS